MARKET

BBI

BBI

Brickell Biotech Inc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

3.741
+0.171
+4.79%
Opening 12:19 07/07 EDT
OPEN
3.540
PREV CLOSE
3.570
HIGH
3.830
LOW
3.540
VOLUME
76.84K
TURNOVER
167.06K
52 WEEK HIGH
38.30
52 WEEK LOW
3.510
MARKET CAP
9.93M
P/E (TTM)
-0.1824
1D
5D
1M
3M
1Y
5Y
Brickell Biotech to Participate at William Blair Biotech Focus Conference 2022
BOULDER, Colo., July 06, 2022 (GLOBE NEWSWIRE) -- Brickell Biotech, Inc. (“Brickell” or the “Company”) (Nasdaq: BBI), a clinical-stage pharmaceutical company striving to transform patient lives by developing innovative and differentiated prescription thera...
GlobeNewswire · 1d ago
Brickell Biotech (BBI) Stock Gains 50% Ahead of Meeting to Prevent Delisting
Investor Place · 06/29 19:02
Brickell Biotech Chief Accounting Officer Resigns; Successor Named
MT Newswires · 06/07 16:48
BRIEF-Brickell Biotech Inc Entered Into A Subscription And Investment Representation Agreement
reuters.com · 05/25 20:57
Brickell Biotech begins dosing in phase 1 trial of oral drug BBI-02 for eczema
Brickell Biotech (NASDAQ:BBI) said the first patients were dosed in the single ascending dose (SAD) portion of a phase 1 trial of BBI-02 capsules in healthy adults and patients with atopic
Seekingalpha · 05/19 15:07
Brickell Biotech Doses First Subject In Phase 1 Study Of DYRK1A Inhibitor BBI-02
– BBI-02 is a potential first-in-class, oral DYRK1A inhibitor with strong preclinical validation and broad potential to treat debilitating autoimmune and inflammatory diseases – – Topline results from
Benzinga · 05/19 12:04
Brickell Biotech Begins Dosing in Phase 1 Trial of Atopic Dermatitis Treatment
MT Newswires · 05/19 10:03
BRIEF-Brickell Biotech Plans To Hold Special Meeting Of Stockholders On June 30, To Consider Another Reverse Stock Split Proposal
reuters.com · 05/17 20:59
More
No Data
Learn about the latest financial forecast of BBI. Analyze the recent business situations of Brickell Biotech Inc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 4 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

50.00%Strong Buy
50.00%Buy
0.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average BBI stock price target is 48.75 with a high estimate of 90.00 and a low estimate of 11.25.
High90.00
Average48.75
Low11.25
Current 3.741
EPS
Actual
Estimate
-5.76-4.32-2.88-1.44
Q2 2021
Q3 2021
Q4 2021
Q1 2022
Q2 2022
Institutional Holdings
Institutions: 46
Institutional Holdings: 763.47K
% Owned: 28.77%
Shares Outstanding: 2.65M
TypeInstitutionsShares
Increased
7
10.24K
New
1
17
Decreased
6
50.77K
Sold Out
8
18.61K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+2.71%
Pharmaceuticals & Medical Research
+0.59%
Key Executives
Chairman/Co-Founder/Director
Reginald Hardy
Chief Executive Officer/Director
Robert Brown
Co-Founder/Chief Operating Officer/Secretary
Andrew Sklawer
Chief Financial Officer/Chief Accounting Officer
Albert Marchio
Chief Compliance Officer/General Counsel
David McAvoy
Other
Deepak Chadha
Other
Monica Luchi
Independent Director
Gary Lyons
Independent Director
Vijay Samant
Independent Director
Dennison Veru
No Data
No Data
About BBI
Brickell Biotech, Inc. is a clinical-stage pharmaceutical company engaged in developing prescription therapeutics for the treatment of autoimmune, inflammatory, and other debilitating diseases. The Company’s pipeline combines several development-stage candidates and a cutting-edge platform with autoimmune and inflammatory disorders program for the treatment of primary axillary hyperhidrosis. Its products include Cialis, Taltz, Gemzar, Prozac, Cymbalta and Juvederm. Its lead development-stage program, BBI-02, is a Phase I ready, highly selective, and orally bioavailable DYRK1A inhibitor that has demonstrated in various preclinical models, including atopic dermatitis and rheumatoid arthritis. BBI-10, the Company’s lead early-stage STING inhibitor candidate, is a novel, potent, and orally available covalent STING inhibitor that specifically targets the palmitoylation site of STING, which allows to inhibit both wild-type STING and gain-of-function mutants.

Webull offers kinds of Brickell Biotech Inc stock information, including NASDAQ:BBI real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, BBI stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading BBI stock methods without spending real money on the virtual paper trading platform.